Humacyte, Inc. cash flow to debt ratio of -161.99% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Humacyte, Inc.'s free cash flow has decreased 6.25% from $-99.69M last year to $-105.93M, signaling decreasing performance

Humacyte, Inc.'s debt to equity ratio is 5.67, which means that the company's assets are unhealthy financed, signaling financial risk.

Humacyte, Inc.'s debt has increased relative to shareholder equity from -0.31 last year to 5.67 today, signaling weakened financials

Humacyte, Inc. has negative EBITDA, making leverage ratio unreliable

Humacyte, Inc.'s interest coverage ratio is -10.82, which means that the company struggles to meet interest obligations, signaling financial risk.

Humacyte, Inc. has insufficient data to evaluate this check.

Humacyte, Inc.'s short-term assets of $67.80M exceed its short-term liabilities of $18.37M

Humacyte, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Humacyte, Inc.'s return on equity of -2.78K%, is lower than 15.00%, indicating bad performance

Humacyte, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Humacyte, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Humacyte, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Humacyte, Inc. has negative free cash flow, indicating cash burn

Humacyte, Inc.'s yearly earnings has increased -72.54% since last year from $-148.70M to $-40.83M, signaling increasing performance

Humacyte, Inc.'s yearly revenue has increased % since last year from $0.00 to $2.04M, signaling increasing performance

ROIC -117.66% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Humacyte, Inc.'s 3-year revenue CAGR of 9.20% is positive, indicating growing revenue over the past 3 years

Humacyte, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Humacyte, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Humacyte, Inc. has insufficient data to evaluate this check.

Humacyte, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Humacyte, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Humacyte, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Humacyte, Inc. has insufficient data to evaluate this check.

Humacyte, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Humacyte, Inc. has a price-to-book ratio of 12.66x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Humacyte, Inc. has a price-to-sales ratio of 72.99x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue